Cognition Therapeutics Inc
CGTX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$0.72
KIRA · Stoqly’s AI analyst, in plain words
- Cognition Therapeutics Inc lost $23.5M in fiscal 2025.
Market cap
$65.1M
P/E
—
Revenue
—
Net income
−$23.5M
Free cash flow
—
Operating margin
—
Cognition Therapeutics Inc in 30 seconds · fiscal 2025
Does it make a profit?
−$23.5M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Cognition Therapeutics Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- COGNITION THERAPEUTICS INC
- CIK
- 0001455365
Cognition Therapeutics Inc · CGTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$0.9M | −$0.0M | −$0.0M | — | — |
| Net interest income | −$0.9M | −$0.0M | −$0.0M | — | — |
| Operating margin | 3,202.5% | 155,539.3% | 187,866.7% | — | — |
| Net income | −$11.7M | −$21.4M | −$25.8M | −$34.0M | −$23.5M |
| Net margin | 1,312.0% | 76,417.9% | 95,511.1% | — | — |
| Diluted EPS | −$3.13 | −$0.91 | −$0.86 | −$0.86 | −$0.32 |
| Cash | |||||
| Cash from operations | −$3.6M | −$18.5M | −$16.0M | −$28.5M | −$24.6M |
| Capital expenditure | $0.0M | $0.2M | $0.1M | $0.0M | — |
| Free cash flow | −$3.7M | −$18.7M | −$16.2M | −$28.5M | — |
| FCF margin | 409.6% | 66,800.0% | 59,870.4% | — | — |
| Share count change | 921.6% | 355.4% | 27.0% | 32.3% | 83.2% |
| Debt and strength | |||||
| Cash and short-term investments | $54.7M | $41.6M | $29.9M | $25.0M | $36.8M |
| Shareholders' equity | $51.3M | $40.2M | $24.5M | $18.8M | $34.3M |
| Current ratio | 7.5x | 6.1x | 3.4x | 2.7x | 3.4x |
| Interest coverage | −32.0x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | — | −46.8% | −79.7% | −157.2% | −88.6% |
| Return on tangible equity | −31.7% | −53.2% | −105.4% | −181.2% | −68.5% |
| Piotroski F-score | 4 | 2 | 1 | — | — |
| Altman Z'' | 4.1 | −3.9 | −15.9 | −25.2 | −12.9 |
Insiders bought, 12 months
$0.0M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cognition Therapeutics Inc · CGTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.72 a share, the company is worth $65.1M.
Source: SEC EDGAR XBRL filings (CIK 0001455365). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.